Overview
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Status:
Terminated
Terminated
Trial end date:
2009-12-01
2009-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units [IU]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Epoetin Alfa
Criteria
Inclusion Criteria:- Adult patients with a non-myeloid malignancy
- Anemia
Exclusion Criteria:
- Transfusion of red blood cells within 2 months of study drug
- Treatment-resistant hypertension
- Acute or chronic bleeding (requiring therapy) within 3 months of study drug